Evidence map›Paper›PMID 28446209›Full record

ArticleAlzheimer's research & therapy2017

Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.

Karim Tifratene, Valeria Manera, Roxane Fabre, Auriane Gros, Susanne Thummler, Christian Pradier, Philippe Robert, Renaud David

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Ayurvedic Medicine for the Treatment of Dementia: Mechanistic Aspects.Evidence-based complementary and alternative medicine : eCAM · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karim TifrateneEA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
Valeria ManeraEA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
Roxane FabreEA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
Auriane GrosEA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
Susanne ThummlerEA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
Christian PradierDepartment of Public Health, L'Archet Hospital, Nice University Hospital, Nice, France.
Philippe RobertEA Cobtek, University of Nice Sophia-Antipolis, Nice, France.
Renaud DavidEA Cobtek, University of Nice Sophia-Antipolis, Nice, France. david.r@chu-nice.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSafety warnings from health authorities are currently intended to limit the use of antipsychotics (APs) in dementia-related conditions to treat neuropsychiatric symptoms, such as disturbing and/or delusional behaviors. The aim of this study is to investigate prevalence, correlates and trends of AP prescribing among people with dementia between 2010 and 2014 in the French population.

methodsAP prescribing and associated factors among individuals with AD, mixed dementia and vascular dementia in the French National Alzheimer Database between 2010 and 2014 were analyzed using multivariate generalized estimating equations models (n = 199,549).

resultsIn 2014, 7.7% of people with dementia were prescribed an AP. Compared with 2010 there was a 16% increase in AP use. Multivariate analysis showed a linear increase risk of prescription with an adjusted odds ratio (95% confidence interval) of 1.23 (1.17-1.30) in 2014 compared with 2010. Factors associated with AP prescribing were male gender, more severe cognitive decline and living in long-term care facilities. Older age and higher education were protective toward AP prescribing. The type of dementia did not have any influence on AP prescribing.

conclusionAn increase in AP prescribing among individuals with dementia in French specialized settings over the last 5 years occurred despite safety warnings. This phenomenon suggests that alternative solutions for the management of behavioral and psychiatric symptoms in these populations are still urgently needed.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAntipsychotic AgentsCross-Sectional StudiesDementiaDrug PrescriptionsFemaleFranceHumansLongitudinal StudiesMaleMedicinePractice Patterns, Physicians'Prescription Drug OverusePrevalenceAntipsychotic AgentsAlzheimer’s diseaseAntipsychoticsDementiaDrug prescribingFrench Alzheimer Database

Identifiers

PMID28446209
PMCPMC5405526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.